Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta Deal
October 4, 2016 1:38 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Summit Therapeutics plc (NASDAQ: SMMT) to $30.00 (from $22.00) after the company licensed out European rights to Phase II candidate ezutromid to Sarepta.
Messer commented, "We believe this deal... More
Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)
October 4, 2016 9:31 AM EDTOppenheimer affirms Summit Therapeutics (Nasdaq: SMMT) at Outperform with a price target of $28 following a new deal with Sarepta (Nasdaq: SRPT).
The firm said, Summit and Sarepta announced this morning a license and collaboration agreement... More
Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'
October 4, 2016 9:13 AM EDTBaird affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $102 following a new licensing agreement with Summit Therapeutics (Nasdaq: SMMT).
Analyst Brian Skorney noted that there was no change to the firm's outlook on Sarepta... More
Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBC
October 4, 2016 9:01 AM EDTRBC Capital analyst Simos Simeonidis said he likes Sarepta Therapeutic (NASDAQ: SRPT) EU/LatAm partnership with Summit (NASDAQ: SMMT), as it removes a potential competitive threat with just $40M for access to competitor's drugs. He also said it makes the Sarepta more attractive as a takeover.
"Buying into this early-stage potential... More
Summit Therapeutics (SMMT) Surges 80% on Sarepta (SRPT) Deal
October 4, 2016 8:56 AM EDTSummit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after the company entered an exclusive... More
Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator Pipeline
October 4, 2016 7:02 AM EDTSarepta Therapeutics (Nasdaq: SRPT) and Summit Therapeutics plc (Nasdaq: SMMT) announced that they have entered into an exclusive license and collaboration agreement granting Sarepta rights in Europe, as well as in Turkey and the Commonwealth of Independent States (the licensed territory), to Summits utrophin modulator pipeline, including its lead clinical candidate, ezutromid, for the treatment of Duchenne muscular dystrophy (DMD). As part of the agreement, Sarepta also obtains an option to license Latin American rights to Summits utrophin modulator pipeline. Summit retains commercialization rights in all other... More
